Video Article

Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model

Ya-Wen Du*[1], Qun Liu*[1], Xiao-Cui Luo[1], Dong-Xiao Zhao[1], Jian-Bo Xue[1], Pu Feng[2], Robert F. Margolskee[2], Hong Wang[2], Liquan Huang[1,2]

[1]College of Life Sciences, Zhejiang University

[2]Monell Chemical Senses Center

*These authors contributed equally

Correspondence to: Hong Wang at hwang@monell.org, Liquan Huang at huangliquan@zju.edu.cn

Abstract

Inflammatory bowel disease (IBD) is one of the immune-related gastrointestinal disorders, including ulcerative colitis and Crohn's disease, that affects the life quality of millions of people worldwide. IBD symptoms include abdominal pain, diarrhea, and rectal bleeding, which may result from the interactions among gut microbiota, food components, intestinal epithelial cells, and immune cells. It is of particular importance to assess how each key gene expressed in intestinal epithelial and immune cells affects inflammation in the colon. G protein-coupled taste receptors, including G protein subunit α-gustducin and other signaling proteins, have been found in the intestines. Here, we use α-gustducin as a representative and describe a dextran sulfate sodium (DSS)-induced IBD model to evaluate the effect of gustatory gene mutations on gut mucosal immunity and inflammation. This method combines gene knockout technology with the chemically induced IBD model, and thus can be applied to assess the outcome of gustatory gene nullification as well as other genes that may exuberate or dampen the DSS-induced immune response in the colon. Mutant mice are administered with DSS for a certain period during which their body weight, stool, and rectal bleeding are monitored and recorded. At different timepoints during administration, some mice are euthanized, then the sizes and weights of their spleens and colons are measured and gut tissues are collected and processed for histological and gene expression analyses. The data show that the α-gustducin knockout results in excessive weight loss, diarrhea, intestinal bleeding, tissue damage, and inflammation *vs.* wild-type mice. Since the severity of induced inflammation is affected by mouse strains, housing environment, and diet, optimization of DSS concentration and administration duration in a pilot experiment is particularly important. By adjusting these factors, this method can be applied to assess both anti- and pro-inflammatory effects.

Video Link

The video component of this article can be found at https://www.jove.com/video/58668/

Introduction

The two major forms of inflammatory bowel disease (IBD), Crohn's disease (CD), and ulcerative colitis (UC) are characterized by chronic remittent or progressive inflammatory conditions of the intestine with multifactorial etiology[1,2]. The development of IBD depends on genetic as well as certain environmental factors such as diet, antibiotic use, and importantly, pathogenic infections. However, the etiology and regulatory molecular mechanisms underlying IBD are still unclear. Hence, numerous chemically induced IBD animal models have been constructed and applied to delineate the pathogenesis and regulatory mechanisms and evaluate the effectiveness of human therapeutics[3].

Taste receptors are G protein-coupled receptors (GPCRs) and are classified as two major types: type I (T1Rs), and type II (T2Rs) that detect sweet, umami, and bitter compounds. Taste signaling cascades are initiated by tastant binding to T1Rs or T2Rs, activating the heterotrimeric G proteins consisting of α-gustducin and a Gβγ dimer and leading to release of the Gβγ subunits. The Gβγ moiety in turn stimulates the downstream effector enzyme phospholipase C-β2 (PLC-β2). Activated PLC-β2 then hydrolyzes phosphatidylinositol-4,5-bisphosphate into two intracellular secondary messengers [inositol-1,4,5-trisphosphate (IP_3) and diacylglycerol], and IP_3 binds to and open its channel-receptor IP_3R3, releasing calcium ions from the endoplasmic reticulum. This eventually leads to the opening of transient receptor potential ion channel Trpm5 and release of the neurotransmitter ATP onto the gustatory nerves[4,5,6,7]. Yet, the signaling pathways of salty and sour tastes are different and independent from sweet, umami, and bitter tastes[8]. In addition, the components of taste GPCRs and downstream proteins exist in various extra-oral tissues. Recent studies indicated that α-gustducin, the principal component of taste signaling, is found to be expressed in the intestinal mucosa. Further studies are needed to understand the functions of these taste signaling components in extra-oral tissues[9,10].

The method described here is used to characterize functions of the gustatory signaling proteins expressed in extra-oral tissues. We combine a transgenic mouse line developed for delineating signaling cascades in taste buds with the chemically induced colitis model. Largely due to its procedural simplicity and pathological similarities to human ulcerative colitis, the dextran sulfate sodium (DSS)-induced IBD model has been

most widely used among the various chemically induced colitis models[11]. In this study, we used α-gustducin-deficient mice as a representative mouse line to reveal novel functions of α-gustducin in gut mucosal immunity and inflammation by 1) analyzing morphological changes in the tissue and 2) assaying differences in the expression of cytokines related to inflammation in the colon. This method can be used to quantitatively and qualitatively determine the contributions of gustatory signaling proteins (and other proteins expressed in the gut) to tissue damage and intestinal inflammation, when genetically modified mouse lines for the genes of interest are available. Advantages of this method are enabling users to obtain integrated data resulting from actions of both the chemical DSS and deficiency of the gene of interest. This method can be further improved to increase its sensitivity and reveal subtle intestinal changes at the cellular and molecular levels.

Protocol

All experiments involving mice were reviewed and approved by the Institutional Animal Care and Use Committees of Zhejiang University. It is advised to wear appropriate personal protective equipment before performing this protocol.

1. Preparation of Mice and DSS

1. Keep the knockout (α-gustducin$^{-/-}$) mice and age-, gender-, and body weight-matched wild-type control (α-gustducin$^{+/+}$) C57BL/6 mice individually in clean cages.
   NOTE: The knockout mice have been backcrossed with C57BL/6 mice for over 20 generations and have a nearly 100% C57BL/6 genetic background.
2. Dissolve 30 g of dextran sulfate sodium (DSS) powder in 1 L of autoclaved water. Mix until the solution becomes clear to ensure that the final working concentration is 3% (w/v).
   NOTE: The DSS solution can be stored at room temperature for up to 1 week or at 4 °C until use.

2. Induction and Evaluation of DSS Colitis in Mice

1. Weigh and record each mouse's initial body weight. Place the mice individually into standard plastic cages and label the cages.
2. Replace regular drinking water with 3% DSS solution for a total of 7 days to which both groups of mice have access *ad libitum*.
3. Measure the mouse's body weight, record DSS solution consumption, and collect and examine the stool of each mouse daily during the DSS administration. Observe the severity of diarrhea and rectal bleeding and convert this to the DSS-induced disease index[12].
4. During the experiment, the percentage of weight loss compared to initial weight and the disease index are calculated to evaluate the symptoms of colitis.
   NOTE: The disease index is scored by combining observations of diarrhea and rectal bleeding and are defined as follows: 0 (normal stool, no blood), 1 (soft stool, no blood), 2 (soft stool, little blood), 3 (very soft stool, modest bleeding), and 4 (watery stool, significant bleeding)[12]. The disease index is analyzed daily for each mouse.
5. By the end of 7-day DSS treatment, sacrifice the mice by cervical dislocation and proceed with the remaining experiments.

3. Preparation of Tissue Samples

1. Place the mouse in the supine position and clean the skin of the abdomen with 70% ethanol. Make a 3 cm-long midline incision in the abdomen with a pair of small scissors to expose the abdominal cavity.
2. Use a pair of forceps to carefully separate the spleen from other tissues, then remove the spleen and measure its size.
3. Identify and lift the colon with forceps and separate it from the surrounding mesentery. Pull out the whole colon until the cecum and rectum are visible.
4. Isolate the colon by transecting it at the colonocecal margin and deep in the pelvis to free the proximal and distal colon, respectively. Then, measure and record the length of the isolated colon. Be careful not to damage the colonic tissue during the dissecting procedure.
5. Flush the colon with 10 mL of ice-cold phosphate-buffered saline (PBS) with a 10 mL syringe equipped with a gavage needle to remove the feces and blood until the eluate is completely clear.
6. For histological identification, divide the tissue samples equally into three parts: proximal, middle, and distal. Then, fix the tissue with 4% paraformaldehyde (PFA) overnight at 4 °C.
7. For the analysis of cytokine expression, freeze the entire colon rapidly with liquid nitrogen and store it at -80 °C until use.

4. Histological Assessment of the Severity of DSS-induced Colitis

1. Hematoxylin and eosin (H&E) staining
   1. After fixation, submerge the tissue in a solution of 30% sucrose in 1x PBS overnight in a 15 mL tube to cryoprotect the samples.
   2. Embed the tissue in optimal cutting temperature (OCT) compound and place it at -20 °C until the OCT hardens.
   3. Transfer the OCT block containing the tissue to a cryostat, set the thickness dial in the cryostat to 12 μm, and slice and collect 12 μm-thick frozen sections.
   4. Heat the collected tissue sections from a cryostat at 65 °C for 20 min on a hot plate.
   5. Wash the sections briefly in distilled water. Stain them with hematoxylin staining solution for 5 min and subsequently rinse with running tap water for 5 min.
   6. Differentiate the sections with 0.5% hydrochloric acid-ethanol for 30 s and rinse them in running tap water for 1 min. Then, perform the wash in 1x PBS for 1 min and subsequently rinse with running tap water for 5 min.
   7. Perform washing of the tissue sections in 70%, 75%, 80%, and 95% alcohol, each for 10 s. Counterstain in eosin staining solution for 2 min.

8. Perform dehydration through 95% alcohol and 2 changes of absolute alcohol for 5 min each time. Clear in 2 changes of xylene for 5 min.
9. Score tissue damage of the proximal, middle, and distal colon of each mouse for both the gene knockout and wild-type groups based on results of the above H&E staining.
   NOTE: The disease index is a combined score of epithelial damage and inflammation in the mucosa, submucosa, muscularis, and serosa regions, which is defined as follows: 0 (no tissue damage and inflammation), 1 (focal tissue damage and inflammation), 2 (patchy tissue damage and inflammation), and 3 (diffuse tissue damage and inflammation)[12,13]. Three scores per mouse for the proximal, middle, and distal parts of the colon are then summed to obtain a total score for each animal. The average scores for each group are then calculated.

2. Immunohistochemistry[14]
   1. Heat the collected tissue sections from a cryostat at 65 °C for 20 min on a hot plate. Wash the sections in 1x PBS 3 times, for 10 min each. Incubate the tissue sections in 3% hydrogen peroxide for 10 min to eliminate endogenous peroxidase. Wash the sections 3 more times. Block the tissues with blocking buffer (3% BSA, 0.3% non-ionic detergent, 2% goat serum, 0.1% sodium azide in 1x PBS) at room temperature for 1 h or more.
   2. Replace the blocking buffer with a solution containing the following immune cell type-specific primary antibodies: CD45 for leukocytes, CD3 for T cells, B220 for B cells, CD11b for macrophages, and Ly6G for neutrophils. Incubate at 4 °C overnight.
   3. Remove the primary antibodies from tissue sections by aspiration. Wash the sections with 1x PBS 3 times, for 10 min each. Incubate the sections with biotinylated secondary antibody followed by incubation with the streptavidin-HRP complex at room temperature.
   4. Incubate the sections with 3,3'-diaminobenziding (DAB) solution to develop a light- or dark-brown color and visualize the immunoreactive cells.
   5. Counterstain the sections with hematoxylin and 0.3% (v/v) diluted ammonia. Take bright-field images at 10X magnification under a microscope.
   6. Use an image processing program to identify and quantify the population of the marked immune cells in both the epithelium and the lamina propria (underneath the epithelium) by setting 2 masks: use the first mask in the color-cube-based feature to set a color detection threshold and measure the colored DAB-reactive areas; use the second mask to determine total areas of the epithelium and laminar propria in the examined section. Express the immunoreactive cell population as a ratio of the staining area of the infiltrated cells to the total area of the examined tissue.

5. Gene Expression Assessment of DSS-induced Colitis

1. Retrieve the colon tissues from the DSS-treated gene knockout and wild-type mice from a -80 °C freezer and add 0.6 mL of lysis buffer to 25 mg of tissue, then homogenize in a homogenizer.
2. Follow the RNA extraction kit's protocol to extract the total RNA, and DNase I is used to eliminate any contaminating genomic DNA.
3. Run an agarose gel to check the quality of the extracted RNA. If its 28S RNA band is brighter than 18S band, it is usable. Take 1 μL of the RNA sample to determine the RNA concentration on a microspectrophotometer.
4. Mix 1 μg of the total RNA with 2.5 μL of 20 mM oligo (dT)[12,13,14,15,16,17,18] primers and 1 μL of Moloney murine leukemia virus (MMLV) reverse transcriptase. Incubate at 42 °C for 60 min to prepare the cDNA.
5. Set up real-time PCR reactions by mixing 1μL of the cDNA with 0.5 μL of forward and reverse qPCR primers for TNF, IFN-γ, IL-5, IL-13, IL-10, TGF-β1, and β-Actin as a control in addition to 2x fluorescent green dye.
6. Run the qPCR with the following parameters: 95 °C for 10 min, followed by 45 cycles of 95 °C for 10 s, 50 °C for 25 s, and 72 °C for 20 s.
7. Calculate the relative quantification of gene expression by using the $2^{-\Delta\Delta Ct}$ method[15]. Comparatively analyze the gene expression levels in the knockout vs. wild-type mice.

Representative Results

A DSS-induced IBD procedure was established by administrating 3% DSS in drinking water to α-gustducin-knockout (KO) and wild-type (WT) mice. Compared to WT mice, the knockout mice exhibited more severe colitis with excessive weight loss, diarrhea, and intestinal bleeding (**Figure 1**). After a 7 day DSS administration, the differences in tissue integrity were analyzed using H&E staining as the histological method, and more aggravated tissue damage was found in the proximal, middle, and distal colons of the knockout mice than in WT mice (**Figure 2**). Furthermore, the excessive immune activation led to colitis with infiltration of various inflammatory cells such as macrophages and neutrophils. Immunohistochemical analyses using a number of markers for the immune cells were carried out to determine whether the α-gustducin deficiency affected immune cell infiltration. Comparative analysis showed that the infiltration of leukocytes, neutrophils, and macrophages was significantly increased in the knockout mice compared to WT control mice (**Figure 3**). Finally, some cytokine expression levels in the colons of DSS-induced colitis mice were determined using qPCR with gene-specific primers. Results showed that compared to WT mice, the knockout mice had higher expression levels of TNF and IFN-γ but lower expression levels of IL-5, IL-13, and IL-10; however, no difference was seen in the expression level of TGF-β1 between the knockout and WT mice (**Figure 4**).

Figure 1: DSS administration renders more severe colitis in α-gustducin knockouts (KO). (**A**) Percentage of body weight loss: KO mice displayed significantly more body weight loss starting from day 3. (**B**) Colitis disease index based on the severity of diarrhea and rectal bleeding: KO mice showed significantly greater disease indices than WT controls. (**C**) Colon (upper panel) and spleen (lower panels) from representative WT and KO mice 7 days post-DSS administration: KO mice had significantly shorter colons and larger spleens. Error bars represent SEM (*p < 0.05, **p < 0.005, ***p < 0.0005; ANOVA with post hoc t-tests). Scale bar = 1 cm. This figure has been modified from a previous publication[13]. Please click here to view a larger version of this figure.


Figure 2: α-gustducin KO mice show more severe tissue damage following DSS treatment. (**A**) H&E staining of colon tissues from WT and α-gustducin KO mice not treated with DSS (water) or treated with DSS for 7 days (DSS). (**B**) Tissue injury scores based on histological staining of colon tissues from WT and KO mice 7 days after DSS administration. DSS treatment induced some tissue damage in WT colons, which was much worse in the KO specimen. Error bars represent SEM (*p < 0.05). Scale bar = 50 μm. This figure has been modified from a previous publication[13]. Please click here to view a larger version of this figure.


Figure 3: α-gustducin KO mice display increased infiltration of immune cells in DSS-induced colitis. (**A**) Massive immune cell infiltration in the colons of DSS-treated KO mice. (**B**) Quantification of immune cell numbers: the percentage of immunostained areas divided by the total area of measured tissue based on image analyses. Error bars represent SEM. Scale bar = 50 μm. This figure has been modified from a previous publication[13]. Please click here to view a larger version of this figure.

Figure 4: α-gustducin KO mice display different expression levels of immune cytokines in DSS-induced colitis. DSS treatment increased expression of TNF and IFN-γ and decreased expression of IL-5, IL-13, and IL-10 in the KO mice colons compared to WT mice. Real-time quantitative RT-PCR was performed using gene-specific primers. β-actin was used as an internal control gene. Error bars represent SEM (*$p < 0.05$, **$p < 0.005$). This figure has been modified from a previous publication[13]. Please click here to view a larger version of this figure.

Gene	Acession Number	qPCR primers		Product size (bp)
		Orientation	Sequence 5' to 3'	
β-actin	NM_007393	Forward Reverse	GATTACTGCTCTGGCTCCTA ATCGTACTCCTGCTTGCTGA	142
TNF	NM_013693	Forward Reverse	CTTCTCATTCCTGCTTGTGG ATCTGAGTGTGAGGGTCTGG	140
IFN-γ	NM_008337	Forward Reverse	AGCAACAGCAAGGCGAAAA CTGGACCTGTGGGTTGTTGA	71
IL-5	NM_010558	Forward Reverse	AGCAATGAGACGATGAGGCTT GCATTTCCACAGTACCCCCA	124
IL-13	NM_008355	Forward Reverse	ACAAGACCAGACTCCCCTGT TCTGGGTCCTGTAGATGGCA	128
IL-10	NM_010548	Forward Reverse	AAGGCAGTGGAGCAGGTGAA CCAGCAGACTCAATACACAC	159
TGF-β1	NM_011577	Forward Reverse	AGAGAAGAACTGCTGTGTGC GGGTTGTGTTGGTTGTAGAG	176

Table 1: List of primers used.

Discussion

This method can be employed to quantitively determine the effect of mutations of specific gustatory genes on inflammation in a DSS-induced IBD mouse model. To take full advantage, optimal induction of IBD is a key step. The development of colitis is affected by several factors, including mouse strain, housing environment, intestinal microflora, as well as the genes of interest. It is recommended to perform a pilot experiment with a small number of mice to test different dosages and durations of DSS administration. During the pilot experiment, gross symptoms such as weight loss, diarrhea, intestinal bleeding, and some microscopic changes such as tissue damage, inflammation associated with immune cell infiltration, and expression-level changes of cytokines should be analyzed and compared to control groups that have drinking water without DSS[16,17,18,19]. Severity of the induced colitis can be monitored by analyzing daily changes in mouse body weight and scores of the collected stool during the DSS-treatment period. After DSS treatment, the tissue damage can be assessed by H&E staining on frozen sections of the colon, whereas infiltration of immune cells and expression levels of cytokines can be identified and quantified using immunohistochemistry and qPCR. DSS dosage, administration duration, and diet can be adjusted to reveal subtle effects of gustatory gene mutations on the colonic immune responses. However, the sensitivity of this method may still limit its application to studies on the minimal effects of some other genes. In this case, some modifications can be adopted; for example, by minimizing the variables from individual-specific intestinal microflora by administrating antibiotics.

The DSS-induced colitis model has been used the most extensively among chemical agent-induced IBD models, largely due to its simplicity, rapidity, reproducibility, controllability, and most importantly its similarities to human ulcerative colitis, which is useful in evaluating the effectiveness of human therapeutics[2]. One disadvantage researchers must be aware of is that T and B cells are not required for the development of colitis, which is different from development of the disease in humans. However, it may be useful for studying the role of the innate immune system in the development of acute colitis[2].

This study has established a DSS-induced IBD model using α-gustducin-deficient mice, which can be used to investigate novel functions of the G protein α subunit in gut mucosal immunity and inflammation. The results show that mice lacking α-gustducin are more susceptible to DSS-induced colitis and are accompanied by more severe symptoms, including tissue damage, excessive inflammatory responses, and altered expression of potent cytokines[13]. In agreement with recent findings indicating the involvement of taste-like chemosensory pathways in type II immune responses to gut parasites[20], α-gustducin and other taste signaling proteins may have novel and important functions in the intestinal immune balance. However, the exact molecular mechanisms underlying these skewed immune responses remain to be uncovered.

Furthermore, this method can be applied to study effects of other gustatory genes that are expressed in the colon (*e.g.,* the transient receptor potential ion channel Trpm5, which is critical to sweet, bitter, and umami tastes and expressed in human colonic cells[7]). Finally, the same strategy can be used to discover new functions of key proteins and factors in intestinal immunity and help evaluate the effectiveness of novel treatments of certain human diseases.

Disclosures

The authors declare that they have no competing financial interests.

Acknowledgements

References

1. Kaser, A., Zeissig, S., Blumberg, R. S. Inflammatory Bowel Disease. *Annual Review of Immunology.* **28** (1), 573-621 (2010).
2. Benoit, C., D., A. J., Madhu, M., Matam, V. K. Dextran Sulfate Sodium (DSS)-Induced Colitis in Mice. *Current Protocols in Immunology.* **104** (1), 15.25.11-15.25.14 (2014).
3. Chassaing, B., Darfeuille-Michaud, A. The Commensal Microbiota and Enteropathogens in the Pathogenesis of Inflammatory Bowel Diseases. *Gastroenterology.* **140** (6), 1720-1728.e1723 (2011).
4. Chandrashekar, J., Hoon, M. A., Ryba, N. J. P., Zuker, C. S. The receptors and cells for mammalian taste. *Nature.* **444** (7117), 288-294 (2006).
5. Gilbertson, T. A., Khan, N. A. Cell signaling mechanisms of oro-gustatory detection of dietary fat: Advances and challenges. *Progress in Lipid Research.* **53,** 82-92 (2014).
6. Huang, L., *et al.* Gγ13 colocalizes with gustducin in taste receptor cells and mediates IP3 responses to bitter denatonium. *Nature Neuroscience.* **2** (12), 1055-1062 (1999).
7. Perez, C. A., *et al.* A transient receptor potential channel expressed in taste receptor cells. *Nature Neuroscience.* **5** (11), 1169-1176 (2002).
8. Shigemura, N., Ninomiya, Y. Recent Advances in Molecular Mechanisms of Taste Signaling and Modifying. *International Review of Cell and Molecular Biology.* **323,** 71-106 (2016).
9. Bezençon, C., *et al.* Murine intestinal cells expressing Trpm5 are mostly brush cells and express markers of neuronal and inflammatory cells. *Journal of Comparative Neurology.* **509** (5), 514-525 (2008).
10. Lu, P., Zhang, C.-H., Lifshitz, L. M., ZhuGe, R. Extraoral bitter taste receptors in health and disease. *The Journal of General Physiology.* **149** (2), 181-197 (2017).
11. Wirtz, S., Neufert, C., Weigmann, B., Neurath, M. F. Chemically induced mouse models of intestinal inflammation. *Nature Protocols.* **2,** 541-546 (2007).
12. Chassaing, B., Aitken, J. D., Malleshappa, M., Vijay-Kumar, M. Dextran sulfate sodium (DSS)-induced colitis in mice. *Current Protocols in Immunology.* **104,** Unit 15 (25), (2014).
13. Feng, P., *et al.* Aggravated gut inflammation in mice lacking the taste signaling protein α-gustducin. *Brain, Behavior, and Immunity.* **71,** 23-27 (2018).
14. Feng, P., *et al.* Immune cells of the human peripheral taste system: Dominant dendritic cells and CD4 T cells. *Brain, Behavior, and Immunity.* **23** (6), 760-766 (2009).
15. Livak, K. J., Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods.* **25** (4), 402-408 (2001).
16. Kim, J. J., Shajib, M. S., Manocha, M. M., Khan, W. I. Investigating Intestinal Inflammation in DSS-induced Model of IBD. *Journal of Visualized Experiments.* (60), 3678 (2012).
17. Axelsson, L.-G., Landström, E., Goldschmidt, T. J., Grönberg, A., Bylund-Fellenius, A.-C. Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice: Effects in CD4+-cell depleted, athymic and NK-cell depleted SCID mice. *Inflammation Research.* **45** (4), 181-191 (1996).
18. Egger, B., *et al.* Characterisation of Acute Murine Dextran Sodium Sulphate Colitis: Cytokine Profile and Dose Dependency. *Digestion.* **62** (4), 240-248 (2000).
19. Whittem, C. G., Williams, A. D., Williams, C. S. Murine Colitis Modeling using Dextran Sulfate Sodium (DSS). *Journal of Visualized Experiments.* (35), 1652 (2010).
20. Howitt, M. R., *et al.* Tuft cells, taste-chemosensory cells, orchestrate parasite type 2 immunity in the gut. *Science (New York, N.Y.).* **351** (6279), 1329-1333 (2016).